Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK

P. N. Tasker, H. MacDonald, W. D. Fraser, David M Reid, S. H. Ralston, O. M. E. Albagha

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The PLOD1 gene is situated within a quantitative trait locus for regulation of bone mineral density (BMD) on chromosome 1p36 and is a strong functional candidate for the regulation of BMD and bone quality. PLOD1 encodes the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxegenase (lysyl hydroxylase; EC 1.14.11.4), which catalyses the hydroxylation of lysine residues during the posttranslational modification of type I collagen, the major protein of bone. We investigated the role of PLOD1 as a genetic determinant of osteoporosis by studying two coding polymorphisms located in exon 3 of the PLOD1 gene in relation to BMD and bone loss in a population-based cohort of 678 Scottish women. We observed a significant association between lumbar spine (LS) BMD and a polymorphism at nucleotide 386 (G386A) of PLOD1, which results in an alanine-threonine amino acid change at codon 99 (A99T). Heterozygotes for G386A had significantly reduced LS-BMD when compared with the other genotype groups, and the difference remained significant after correcting for confounding factors. A similar association was observed between LS-BMD and a conservative polymorphism at position 385 (C385T), but this was in strong linkage disequilibrium (LD) with G386A. There was no evidence for an allele dose effect for either polymorphism, and the strongest association was observed in heterozygotes. No association was found between PLOD1 alleles and femoral-neck BMD or bone loss, but the hydroxylysylpyridinoline to lysylpyridinoline ratio was significantly increased in G386A heterozygotes compared with other genotype groups, suggesting a functional effect of this polymorphism on enzyme activity. Our findings show that heterozygosity for the A99T variant of PLOD1 is associated with reduced LS-BMD and an altered ratio of hydroxylysylpyridinoline to lysylpyridinoline. Whilst further studies will be required to confirm and extend these observations, our studies raise the possibility that A99T heterozygosity might affect lysyl hydroxylase function and regulate bone mass.

Original languageEnglish
Pages (from-to)1078-1085
Number of pages8
JournalOsteoporosis International
Volume17
Issue number7
Early online date4 May 2006
DOIs
Publication statusPublished - 2006

Keywords

  • bone mineral density
  • PLOD1
  • polymorphism
  • quantitative trait loci
  • genome screen
  • osteoporosis prevention
  • collagen
  • gene
  • linkage
  • perimenopausal
  • heterosis
  • suggests
  • fracture

Cite this

Tasker, P. N., MacDonald, H., Fraser, W. D., Reid, D. M., Ralston, S. H., & Albagha, O. M. E. (2006). Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK. Osteoporosis International, 17(7), 1078-1085. https://doi.org/10.1007/s00198-006-0129-7

Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK. / Tasker, P. N.; MacDonald, H.; Fraser, W. D.; Reid, David M; Ralston, S. H.; Albagha, O. M. E.

In: Osteoporosis International, Vol. 17, No. 7, 2006, p. 1078-1085.

Research output: Contribution to journalArticle

Tasker, PN, MacDonald, H, Fraser, WD, Reid, DM, Ralston, SH & Albagha, OME 2006, 'Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK', Osteoporosis International, vol. 17, no. 7, pp. 1078-1085. https://doi.org/10.1007/s00198-006-0129-7
Tasker, P. N. ; MacDonald, H. ; Fraser, W. D. ; Reid, David M ; Ralston, S. H. ; Albagha, O. M. E. / Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK. In: Osteoporosis International. 2006 ; Vol. 17, No. 7. pp. 1078-1085.
@article{8b128b902b2b48c6a028ceefe32558a7,
title = "Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK",
abstract = "The PLOD1 gene is situated within a quantitative trait locus for regulation of bone mineral density (BMD) on chromosome 1p36 and is a strong functional candidate for the regulation of BMD and bone quality. PLOD1 encodes the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxegenase (lysyl hydroxylase; EC 1.14.11.4), which catalyses the hydroxylation of lysine residues during the posttranslational modification of type I collagen, the major protein of bone. We investigated the role of PLOD1 as a genetic determinant of osteoporosis by studying two coding polymorphisms located in exon 3 of the PLOD1 gene in relation to BMD and bone loss in a population-based cohort of 678 Scottish women. We observed a significant association between lumbar spine (LS) BMD and a polymorphism at nucleotide 386 (G386A) of PLOD1, which results in an alanine-threonine amino acid change at codon 99 (A99T). Heterozygotes for G386A had significantly reduced LS-BMD when compared with the other genotype groups, and the difference remained significant after correcting for confounding factors. A similar association was observed between LS-BMD and a conservative polymorphism at position 385 (C385T), but this was in strong linkage disequilibrium (LD) with G386A. There was no evidence for an allele dose effect for either polymorphism, and the strongest association was observed in heterozygotes. No association was found between PLOD1 alleles and femoral-neck BMD or bone loss, but the hydroxylysylpyridinoline to lysylpyridinoline ratio was significantly increased in G386A heterozygotes compared with other genotype groups, suggesting a functional effect of this polymorphism on enzyme activity. Our findings show that heterozygosity for the A99T variant of PLOD1 is associated with reduced LS-BMD and an altered ratio of hydroxylysylpyridinoline to lysylpyridinoline. Whilst further studies will be required to confirm and extend these observations, our studies raise the possibility that A99T heterozygosity might affect lysyl hydroxylase function and regulate bone mass.",
keywords = "bone mineral density, PLOD1, polymorphism, quantitative trait loci, genome screen, osteoporosis prevention, collagen, gene, linkage, perimenopausal, heterosis, suggests, fracture",
author = "Tasker, {P. N.} and H. MacDonald and Fraser, {W. D.} and Reid, {David M} and Ralston, {S. H.} and Albagha, {O. M. E.}",
year = "2006",
doi = "10.1007/s00198-006-0129-7",
language = "English",
volume = "17",
pages = "1078--1085",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "SPRINGER-VERLAG LONDON LTD",
number = "7",

}

TY - JOUR

T1 - Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK

AU - Tasker, P. N.

AU - MacDonald, H.

AU - Fraser, W. D.

AU - Reid, David M

AU - Ralston, S. H.

AU - Albagha, O. M. E.

PY - 2006

Y1 - 2006

N2 - The PLOD1 gene is situated within a quantitative trait locus for regulation of bone mineral density (BMD) on chromosome 1p36 and is a strong functional candidate for the regulation of BMD and bone quality. PLOD1 encodes the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxegenase (lysyl hydroxylase; EC 1.14.11.4), which catalyses the hydroxylation of lysine residues during the posttranslational modification of type I collagen, the major protein of bone. We investigated the role of PLOD1 as a genetic determinant of osteoporosis by studying two coding polymorphisms located in exon 3 of the PLOD1 gene in relation to BMD and bone loss in a population-based cohort of 678 Scottish women. We observed a significant association between lumbar spine (LS) BMD and a polymorphism at nucleotide 386 (G386A) of PLOD1, which results in an alanine-threonine amino acid change at codon 99 (A99T). Heterozygotes for G386A had significantly reduced LS-BMD when compared with the other genotype groups, and the difference remained significant after correcting for confounding factors. A similar association was observed between LS-BMD and a conservative polymorphism at position 385 (C385T), but this was in strong linkage disequilibrium (LD) with G386A. There was no evidence for an allele dose effect for either polymorphism, and the strongest association was observed in heterozygotes. No association was found between PLOD1 alleles and femoral-neck BMD or bone loss, but the hydroxylysylpyridinoline to lysylpyridinoline ratio was significantly increased in G386A heterozygotes compared with other genotype groups, suggesting a functional effect of this polymorphism on enzyme activity. Our findings show that heterozygosity for the A99T variant of PLOD1 is associated with reduced LS-BMD and an altered ratio of hydroxylysylpyridinoline to lysylpyridinoline. Whilst further studies will be required to confirm and extend these observations, our studies raise the possibility that A99T heterozygosity might affect lysyl hydroxylase function and regulate bone mass.

AB - The PLOD1 gene is situated within a quantitative trait locus for regulation of bone mineral density (BMD) on chromosome 1p36 and is a strong functional candidate for the regulation of BMD and bone quality. PLOD1 encodes the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxegenase (lysyl hydroxylase; EC 1.14.11.4), which catalyses the hydroxylation of lysine residues during the posttranslational modification of type I collagen, the major protein of bone. We investigated the role of PLOD1 as a genetic determinant of osteoporosis by studying two coding polymorphisms located in exon 3 of the PLOD1 gene in relation to BMD and bone loss in a population-based cohort of 678 Scottish women. We observed a significant association between lumbar spine (LS) BMD and a polymorphism at nucleotide 386 (G386A) of PLOD1, which results in an alanine-threonine amino acid change at codon 99 (A99T). Heterozygotes for G386A had significantly reduced LS-BMD when compared with the other genotype groups, and the difference remained significant after correcting for confounding factors. A similar association was observed between LS-BMD and a conservative polymorphism at position 385 (C385T), but this was in strong linkage disequilibrium (LD) with G386A. There was no evidence for an allele dose effect for either polymorphism, and the strongest association was observed in heterozygotes. No association was found between PLOD1 alleles and femoral-neck BMD or bone loss, but the hydroxylysylpyridinoline to lysylpyridinoline ratio was significantly increased in G386A heterozygotes compared with other genotype groups, suggesting a functional effect of this polymorphism on enzyme activity. Our findings show that heterozygosity for the A99T variant of PLOD1 is associated with reduced LS-BMD and an altered ratio of hydroxylysylpyridinoline to lysylpyridinoline. Whilst further studies will be required to confirm and extend these observations, our studies raise the possibility that A99T heterozygosity might affect lysyl hydroxylase function and regulate bone mass.

KW - bone mineral density

KW - PLOD1

KW - polymorphism

KW - quantitative trait loci

KW - genome screen

KW - osteoporosis prevention

KW - collagen

KW - gene

KW - linkage

KW - perimenopausal

KW - heterosis

KW - suggests

KW - fracture

U2 - 10.1007/s00198-006-0129-7

DO - 10.1007/s00198-006-0129-7

M3 - Article

VL - 17

SP - 1078

EP - 1085

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 7

ER -